Arxx Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

Arxx Therapeutics General Information

Description

Developer of novel disease-modifying therapies intended for rare fibrotic diseases. The company offers novel antifibrotic therapy by modifying the innate and adaptive immune system by targeting the DAMP S100A4 with an antibody and the first indication will be systemic sclerosis, an autoimmune disease that causes fibrosis and tissue dysfunction in multiple organs, enabling patients to avail the treatments.

Contact Information

Website
www.arxxtx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Gaistadalleen 21
  • 0349 Oslo
  • Norway
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Calluna Pharma
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Gaistadalleen 21
  • 0349 Oslo
  • Norway

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arxx Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 25-Jan-2024 Completed Generating Revenue
5. Later Stage VC 20-Jan-2023 Cancelled Generating Revenue
4. Secondary Transaction - Private Completed Clinical Trials - Phase 1
3. Seed Round 04-May-2021 Completed Product In Beta Test
2. Early Stage VC Completed Startup
1. Accelerator/Incubator Completed Startup
To view Arxx Therapeutics’s complete valuation and funding history, request access »

Arxx Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arxx Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
ASTEROIDEBAKKEN Corporation Minority
Altitude Capital Hedge Fund Minority
Andenes Investments Venture Capital Minority
Investinor Venture Capital Minority
Mp Pensjon Asset Manager Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Arxx Therapeutics FAQs

  • When was Arxx Therapeutics founded?

    Arxx Therapeutics was founded in 2015.

  • Where is Arxx Therapeutics headquartered?

    Arxx Therapeutics is headquartered in Oslo, Norway.

  • What is the size of Arxx Therapeutics?

    Arxx Therapeutics has 6 total employees.

  • What industry is Arxx Therapeutics in?

    Arxx Therapeutics’s primary industry is Drug Discovery.

  • Is Arxx Therapeutics a private or public company?

    Arxx Therapeutics is a Private company.

  • What is Arxx Therapeutics’s current revenue?

    The current revenue for Arxx Therapeutics is .

  • How much funding has Arxx Therapeutics raised over time?

    Arxx Therapeutics has raised $13M.

  • Who are Arxx Therapeutics’s investors?

    ASTEROIDEBAKKEN, Altitude Capital, Andenes Investments, Investinor, and Mp Pensjon are 5 of 11 investors who have invested in Arxx Therapeutics.

  • When was Arxx Therapeutics acquired?

    Arxx Therapeutics was acquired on 25-Jan-2024.

  • Who acquired Arxx Therapeutics?

    Arxx Therapeutics was acquired by Calluna Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process